TORNTPHARM - IntraDay Trade Analysis with Live Signals
Last Updated Time : 20 Dec 25, 07:04 am
Back to IntraDay Trade ListIntraDay Trade Rating: 4.0
| Stock Code | TORNTPHARM | Market Cap | 1,28,614 Cr. | Current Price | 3,800 ₹ | High / Low | 3,882 ₹ |
| Stock P/E | 60.2 | Book Value | 250 ₹ | Dividend Yield | 0.85 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 3,704 ₹ | DMA 200 | 3,494 ₹ |
| Chg in FII Hold | -0.17 % | Chg in DII Hold | 0.63 % | PAT Qtr | 606 Cr. | PAT Prev Qtr | 551 Cr. |
| RSI | 52.8 | MACD | 21.6 | Volume | 1,25,995 | Avg Vol 1Wk | 1,45,516 |
| Low price | 2,886 ₹ | High price | 3,882 ₹ | PEG Ratio | 2.48 | Debt to equity | 0.25 |
| 52w Index | 91.8 % | Qtr Profit Var | 31.8 % | EPS | 62.3 ₹ | Industry PE | 30.6 |
📊 Analysis: TORNTPHARM is trading at ₹3,800, close to its 52-week high (₹3,882), showing strong bullish sentiment. Price is above both 50 DMA (₹3,704) and 200 DMA (₹3,494), confirming trend strength. RSI at 52.8 indicates balanced momentum, while MACD at 21.6 supports positive bias. Volume (1.26L) is slightly below average (1.45L), suggesting moderate intraday participation. Strong ROCE (27.8%) and ROE (26.2%) reinforce fundamentals, though valuation remains high with P/E at 60.2 vs industry 30.6.
💹 Optimal Buy Price: ₹3,785–₹3,805 (near current levels with tight entry).
🎯 Profit-Taking Exit Levels: ₹3,840 (short target), ₹3,880 (extended target if momentum sustains).
🛡️ Stop-Loss / Loss Protection: ₹3,760 (below intraday support).
⏱️ If Already Holding: Exit near ₹3,840–₹3,880 if momentum sustains. If RSI rises above 65 or volume weakens further, consider early exit. A break below ₹3,760 should trigger stop-loss.
Positive
- 📈 ROCE 27.8% and ROE 26.2% show strong capital efficiency.
- 💰 Quarter Profit Var +31.8% highlights robust earnings growth.
- 📊 EPS 62.3 ₹ supports earnings visibility.
- 🔥 DII holding increased (+0.63%), reflecting domestic institutional support.
Limitation
- ⚠️ High P/E 60.2 vs industry average (30.6), showing valuation premium.
- 📉 PEG Ratio 2.48 signals expensive valuation relative to growth.
- 📊 Volume below average reduces intraday conviction.
- 📉 Debt-to-Equity 0.25 adds moderate leverage risk.
Company Negative News
- 📉 FII holding reduced (-0.17%), showing foreign investor caution.
Company Positive News
- 📈 DII holding increased (+0.63%), reflecting strong domestic support.
- 📈 PAT improved from ₹551 Cr. to ₹606 Cr., showing earnings momentum.
Industry
- 🌐 Pharma sector trades at PE 30.6, much lower than TORNTPHARM’s valuation.
- 📊 Sector outlook stable, but TORNTPHARM trades at premium requiring momentum-driven entries.
Conclusion
⚖️ TORNTPHARM is a strong intraday candidate with bullish technicals and solid fundamentals. However, high valuation and slightly weaker volume suggest cautious entries with strict stop-loss discipline. Best suited for momentum scalps near resistance levels.
Would you like me to extend this into a pharma sector basket overlay with peers like Sun Pharma, Cipla, and Dr. Reddy’s, so you can benchmark TORNTPHARM’s intraday setup across the industry?
Back to IntraDay Trade ListNIFTY 50 - Today Top Intraday Trade Stock Picks
NEXT 50 - Today Top Intraday Trade Stock Picks
MIDCAP - Today Top Intraday Trade Stock Picks
SMALLCAP - Today Top Intraday Trade Stock Picks